CN110093412A - 用于诊断动脉粥样硬化的分子标志物ugp2及应用 - Google Patents
用于诊断动脉粥样硬化的分子标志物ugp2及应用 Download PDFInfo
- Publication number
- CN110093412A CN110093412A CN201910250626.0A CN201910250626A CN110093412A CN 110093412 A CN110093412 A CN 110093412A CN 201910250626 A CN201910250626 A CN 201910250626A CN 110093412 A CN110093412 A CN 110093412A
- Authority
- CN
- China
- Prior art keywords
- ugp2
- atherosclerosis
- disease
- protein
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100038834 UTP-glucose-1-phosphate uridylyltransferase Human genes 0.000 title claims abstract description 45
- 101000809490 Homo sapiens UTP-glucose-1-phosphate uridylyltransferase Proteins 0.000 title claims abstract 11
- 230000003143 atherosclerotic effect Effects 0.000 title abstract description 6
- 239000003147 molecular marker Substances 0.000 title abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 34
- 201000010099 disease Diseases 0.000 claims abstract description 32
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 27
- 238000013517 stratification Methods 0.000 claims abstract description 8
- 238000003745 diagnosis Methods 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 238000000338 in vitro Methods 0.000 claims abstract description 5
- 230000014509 gene expression Effects 0.000 claims description 20
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 239000000090 biomarker Substances 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 230000000951 immunodiffusion Effects 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 108010033276 Peptide Fragments Proteins 0.000 claims description 2
- 102000007079 Peptide Fragments Human genes 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 230000002596 correlated effect Effects 0.000 claims description 2
- 238000003119 immunoblot Methods 0.000 claims description 2
- 238000000760 immunoelectrophoresis Methods 0.000 claims description 2
- 238000001114 immunoprecipitation Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000004393 prognosis Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims 1
- 238000004043 dyeing Methods 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 9
- 210000001519 tissue Anatomy 0.000 description 7
- 238000001262 western blot Methods 0.000 description 6
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- HSCJRCZFDFQWRP-RDKQLNKOSA-N UDP-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-RDKQLNKOSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 3
- 101710088074 UTP-glucose-1-phosphate uridylyltransferase 2 Proteins 0.000 description 3
- 102000048175 UTP-glucose-1-phosphate uridylyltransferases Human genes 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- OEROYDLRVAYIMQ-YUMQZZPRSA-N His-Gly-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O OEROYDLRVAYIMQ-YUMQZZPRSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- RFQATBGBLDAKGI-VHSXEESVSA-N Lys-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCCN)N)C(=O)O RFQATBGBLDAKGI-VHSXEESVSA-N 0.000 description 2
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 2
- 108700023183 UTP-glucose-1-phosphate uridylyltransferases Proteins 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 108010089804 glycyl-threonine Proteins 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 108010025306 histidylleucine Proteins 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 108010073969 valyllysine Proteins 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- HJGZVLLLBJLXFC-LSJOCFKGSA-N Ala-His-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(O)=O HJGZVLLLBJLXFC-LSJOCFKGSA-N 0.000 description 1
- XCIGOVDXZULBBV-DCAQKATOSA-N Ala-Val-Lys Chemical compound CC(C)[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCCN)C(O)=O XCIGOVDXZULBBV-DCAQKATOSA-N 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- MCYJBCKCAPERSE-FXQIFTODSA-N Arg-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N MCYJBCKCAPERSE-FXQIFTODSA-N 0.000 description 1
- RVDVDRUZWZIBJQ-CIUDSAMLSA-N Arg-Asn-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O RVDVDRUZWZIBJQ-CIUDSAMLSA-N 0.000 description 1
- OQCWXQJLCDPRHV-UWVGGRQHSA-N Arg-Gly-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O OQCWXQJLCDPRHV-UWVGGRQHSA-N 0.000 description 1
- YKBHOXLMMPZPHQ-GMOBBJLQSA-N Arg-Ile-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O YKBHOXLMMPZPHQ-GMOBBJLQSA-N 0.000 description 1
- GMFAGHNRXPSSJS-SRVKXCTJSA-N Arg-Leu-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GMFAGHNRXPSSJS-SRVKXCTJSA-N 0.000 description 1
- DPLFNLDACGGBAK-KKUMJFAQSA-N Arg-Phe-Glu Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N DPLFNLDACGGBAK-KKUMJFAQSA-N 0.000 description 1
- VENMDXUVHSKEIN-GUBZILKMSA-N Arg-Ser-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VENMDXUVHSKEIN-GUBZILKMSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- HZPSDHRYYIORKR-WHFBIAKZSA-N Asn-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O HZPSDHRYYIORKR-WHFBIAKZSA-N 0.000 description 1
- FBODFHMLALOPHP-GUBZILKMSA-N Asn-Lys-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O FBODFHMLALOPHP-GUBZILKMSA-N 0.000 description 1
- AYOAHKWVQLNPDM-HJGDQZAQSA-N Asn-Lys-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O AYOAHKWVQLNPDM-HJGDQZAQSA-N 0.000 description 1
- HPBNLFLSSQDFQW-WHFBIAKZSA-N Asn-Ser-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O HPBNLFLSSQDFQW-WHFBIAKZSA-N 0.000 description 1
- QYRMBFWDSFGSFC-OLHMAJIHSA-N Asn-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O QYRMBFWDSFGSFC-OLHMAJIHSA-N 0.000 description 1
- PIABYSIYPGLLDQ-XVSYOHENSA-N Asn-Thr-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PIABYSIYPGLLDQ-XVSYOHENSA-N 0.000 description 1
- JNCRAQVYJZGIOW-QSFUFRPTSA-N Asn-Val-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JNCRAQVYJZGIOW-QSFUFRPTSA-N 0.000 description 1
- GHWWTICYPDKPTE-NGZCFLSTSA-N Asn-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N GHWWTICYPDKPTE-NGZCFLSTSA-N 0.000 description 1
- PQKSVQSMTHPRIB-ZKWXMUAHSA-N Asn-Val-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O PQKSVQSMTHPRIB-ZKWXMUAHSA-N 0.000 description 1
- OVPHVTCDVYYTHN-AVGNSLFASA-N Asp-Glu-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OVPHVTCDVYYTHN-AVGNSLFASA-N 0.000 description 1
- DTNUIAJCPRMNBT-WHFBIAKZSA-N Asp-Gly-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O DTNUIAJCPRMNBT-WHFBIAKZSA-N 0.000 description 1
- OMMIEVATLAGRCK-BYPYZUCNSA-N Asp-Gly-Gly Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)NCC(O)=O OMMIEVATLAGRCK-BYPYZUCNSA-N 0.000 description 1
- KHGPWGKPYHPOIK-QWRGUYRKSA-N Asp-Gly-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O KHGPWGKPYHPOIK-QWRGUYRKSA-N 0.000 description 1
- ORRJQLIATJDMQM-HJGDQZAQSA-N Asp-Leu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O ORRJQLIATJDMQM-HJGDQZAQSA-N 0.000 description 1
- HXVILZUZXFLVEN-DCAQKATOSA-N Asp-Met-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O HXVILZUZXFLVEN-DCAQKATOSA-N 0.000 description 1
- QPDUWAUSSWGJSB-NGZCFLSTSA-N Asp-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N QPDUWAUSSWGJSB-NGZCFLSTSA-N 0.000 description 1
- QOJJMJKTMKNFEF-ZKWXMUAHSA-N Asp-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O QOJJMJKTMKNFEF-ZKWXMUAHSA-N 0.000 description 1
- RKXVTTIQNKPCHU-KKHAAJSZSA-N Asp-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O RKXVTTIQNKPCHU-KKHAAJSZSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- XGIAHEUULGOZHH-GUBZILKMSA-N Cys-Arg-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)N XGIAHEUULGOZHH-GUBZILKMSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- XOKGKOQWADCLFQ-GARJFASQSA-N Gln-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XOKGKOQWADCLFQ-GARJFASQSA-N 0.000 description 1
- OFPWCBGRYAOLMU-AVGNSLFASA-N Gln-Asp-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N)O OFPWCBGRYAOLMU-AVGNSLFASA-N 0.000 description 1
- XJKAKYXMFHUIHT-AUTRQRHGSA-N Gln-Glu-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N XJKAKYXMFHUIHT-AUTRQRHGSA-N 0.000 description 1
- QKCZZAZNMMVICF-DCAQKATOSA-N Gln-Leu-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O QKCZZAZNMMVICF-DCAQKATOSA-N 0.000 description 1
- RSUVOPBMWMTVDI-XEGUGMAKSA-N Glu-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C)C(O)=O)=CNC2=C1 RSUVOPBMWMTVDI-XEGUGMAKSA-N 0.000 description 1
- RDDSZZJOKDVPAE-ACZMJKKPSA-N Glu-Asn-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RDDSZZJOKDVPAE-ACZMJKKPSA-N 0.000 description 1
- VAZZOGXDUQSVQF-NUMRIWBASA-N Glu-Asn-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N)O VAZZOGXDUQSVQF-NUMRIWBASA-N 0.000 description 1
- ALCAUWPAMLVUDB-FXQIFTODSA-N Glu-Gln-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ALCAUWPAMLVUDB-FXQIFTODSA-N 0.000 description 1
- KRGZZKWSBGPLKL-IUCAKERBSA-N Glu-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)N KRGZZKWSBGPLKL-IUCAKERBSA-N 0.000 description 1
- ZCOJVESMNGBGLF-GRLWGSQLSA-N Glu-Ile-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZCOJVESMNGBGLF-GRLWGSQLSA-N 0.000 description 1
- PJBVXVBTTFZPHJ-GUBZILKMSA-N Glu-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)N PJBVXVBTTFZPHJ-GUBZILKMSA-N 0.000 description 1
- YKBUCXNNBYZYAY-MNXVOIDGSA-N Glu-Lys-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YKBUCXNNBYZYAY-MNXVOIDGSA-N 0.000 description 1
- JDUKCSSHWNIQQZ-IHRRRGAJSA-N Glu-Phe-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O JDUKCSSHWNIQQZ-IHRRRGAJSA-N 0.000 description 1
- KXTAGESXNQEZKB-DZKIICNBSA-N Glu-Phe-Val Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=CC=C1 KXTAGESXNQEZKB-DZKIICNBSA-N 0.000 description 1
- HJTSRYLPAYGEEC-SIUGBPQLSA-N Glu-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCC(=O)O)N HJTSRYLPAYGEEC-SIUGBPQLSA-N 0.000 description 1
- PYTZFYUXZZHOAD-WHFBIAKZSA-N Gly-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CN PYTZFYUXZZHOAD-WHFBIAKZSA-N 0.000 description 1
- CCBIBMKQNXHNIN-ZETCQYMHSA-N Gly-Leu-Gly Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CCBIBMKQNXHNIN-ZETCQYMHSA-N 0.000 description 1
- PTIIBFKSLCYQBO-NHCYSSNCSA-N Gly-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)CN PTIIBFKSLCYQBO-NHCYSSNCSA-N 0.000 description 1
- MHXKHKWHPNETGG-QWRGUYRKSA-N Gly-Lys-Leu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O MHXKHKWHPNETGG-QWRGUYRKSA-N 0.000 description 1
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 1
- 108010001483 Glycogen Synthase Proteins 0.000 description 1
- CJGDTAHEMXLRMB-ULQDDVLXSA-N His-Arg-Phe Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O CJGDTAHEMXLRMB-ULQDDVLXSA-N 0.000 description 1
- LVWIJITYHRZHBO-IXOXFDKPSA-N His-Leu-Thr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LVWIJITYHRZHBO-IXOXFDKPSA-N 0.000 description 1
- JUCZDDVZBMPKRT-IXOXFDKPSA-N His-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N)O JUCZDDVZBMPKRT-IXOXFDKPSA-N 0.000 description 1
- LQSBBHNVAVNZSX-GHCJXIJMSA-N Ile-Ala-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)O)N LQSBBHNVAVNZSX-GHCJXIJMSA-N 0.000 description 1
- YKRYHWJRQUSTKG-KBIXCLLPSA-N Ile-Ala-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N YKRYHWJRQUSTKG-KBIXCLLPSA-N 0.000 description 1
- ASCFJMSGKUIRDU-ZPFDUUQYSA-N Ile-Arg-Gln Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O ASCFJMSGKUIRDU-ZPFDUUQYSA-N 0.000 description 1
- NBJAAWYRLGCJOF-UGYAYLCHSA-N Ile-Asp-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N NBJAAWYRLGCJOF-UGYAYLCHSA-N 0.000 description 1
- CCHSQWLCOOZREA-GMOBBJLQSA-N Ile-Asp-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCSC)C(=O)O)N CCHSQWLCOOZREA-GMOBBJLQSA-N 0.000 description 1
- OVPYIUNCVSOVNF-ZPFDUUQYSA-N Ile-Gln-Pro Natural products CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O OVPYIUNCVSOVNF-ZPFDUUQYSA-N 0.000 description 1
- IXEFKXAGHRQFAF-HVTMNAMFSA-N Ile-Glu-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N IXEFKXAGHRQFAF-HVTMNAMFSA-N 0.000 description 1
- VOBYAKCXGQQFLR-LSJOCFKGSA-N Ile-Gly-Val Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O VOBYAKCXGQQFLR-LSJOCFKGSA-N 0.000 description 1
- UIEZQYNXCYHMQS-BJDJZHNGSA-N Ile-Lys-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)N UIEZQYNXCYHMQS-BJDJZHNGSA-N 0.000 description 1
- AKOYRLRUFBZOSP-BJDJZHNGSA-N Ile-Lys-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)O)N AKOYRLRUFBZOSP-BJDJZHNGSA-N 0.000 description 1
- FQYQMFCIJNWDQZ-CYDGBPFRSA-N Ile-Pro-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 FQYQMFCIJNWDQZ-CYDGBPFRSA-N 0.000 description 1
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 1
- DTPGSUQHUMELQB-GVARAGBVSA-N Ile-Tyr-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=C(O)C=C1 DTPGSUQHUMELQB-GVARAGBVSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- OIARJGNVARWKFP-YUMQZZPRSA-N Leu-Asn-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O OIARJGNVARWKFP-YUMQZZPRSA-N 0.000 description 1
- VIWUBXKCYJGNCL-SRVKXCTJSA-N Leu-Asn-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 VIWUBXKCYJGNCL-SRVKXCTJSA-N 0.000 description 1
- POJPZSMTTMLSTG-SRVKXCTJSA-N Leu-Asn-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N POJPZSMTTMLSTG-SRVKXCTJSA-N 0.000 description 1
- CLVUXCBGKUECIT-HJGDQZAQSA-N Leu-Asp-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CLVUXCBGKUECIT-HJGDQZAQSA-N 0.000 description 1
- ZTLGVASZOIKNIX-DCAQKATOSA-N Leu-Gln-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZTLGVASZOIKNIX-DCAQKATOSA-N 0.000 description 1
- FQZPTCNSNPWHLJ-AVGNSLFASA-N Leu-Gln-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O FQZPTCNSNPWHLJ-AVGNSLFASA-N 0.000 description 1
- QVFGXCVIXXBFHO-AVGNSLFASA-N Leu-Glu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O QVFGXCVIXXBFHO-AVGNSLFASA-N 0.000 description 1
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 1
- CCQLQKZTXZBXTN-NHCYSSNCSA-N Leu-Gly-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O CCQLQKZTXZBXTN-NHCYSSNCSA-N 0.000 description 1
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 1
- LVTJJOJKDCVZGP-QWRGUYRKSA-N Leu-Lys-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O LVTJJOJKDCVZGP-QWRGUYRKSA-N 0.000 description 1
- ARRIJPQRBWRNLT-DCAQKATOSA-N Leu-Met-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)N)C(=O)O)N ARRIJPQRBWRNLT-DCAQKATOSA-N 0.000 description 1
- GZRABTMNWJXFMH-UVOCVTCTSA-N Leu-Thr-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZRABTMNWJXFMH-UVOCVTCTSA-N 0.000 description 1
- YLMIDMSLKLRNHX-HSCHXYMDSA-N Leu-Trp-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YLMIDMSLKLRNHX-HSCHXYMDSA-N 0.000 description 1
- ARNIBBOXIAWUOP-MGHWNKPDSA-N Leu-Tyr-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ARNIBBOXIAWUOP-MGHWNKPDSA-N 0.000 description 1
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 1
- ZTPWXNOOKAXPPE-DCAQKATOSA-N Lys-Arg-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O)N ZTPWXNOOKAXPPE-DCAQKATOSA-N 0.000 description 1
- JGAMUXDWYSXYLM-SRVKXCTJSA-N Lys-Arg-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O JGAMUXDWYSXYLM-SRVKXCTJSA-N 0.000 description 1
- IWWMPCPLFXFBAF-SRVKXCTJSA-N Lys-Asp-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O IWWMPCPLFXFBAF-SRVKXCTJSA-N 0.000 description 1
- DCRWPTBMWMGADO-AVGNSLFASA-N Lys-Glu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DCRWPTBMWMGADO-AVGNSLFASA-N 0.000 description 1
- KEPWSUPUFAPBRF-DKIMLUQUSA-N Lys-Ile-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O KEPWSUPUFAPBRF-DKIMLUQUSA-N 0.000 description 1
- XREQQOATSMMAJP-MGHWNKPDSA-N Lys-Ile-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XREQQOATSMMAJP-MGHWNKPDSA-N 0.000 description 1
- VMTYLUGCXIEDMV-QWRGUYRKSA-N Lys-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN VMTYLUGCXIEDMV-QWRGUYRKSA-N 0.000 description 1
- XIZQPFCRXLUNMK-BZSNNMDCSA-N Lys-Leu-Phe Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCCCN)N XIZQPFCRXLUNMK-BZSNNMDCSA-N 0.000 description 1
- GAHJXEMYXKLZRQ-AJNGGQMLSA-N Lys-Lys-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O GAHJXEMYXKLZRQ-AJNGGQMLSA-N 0.000 description 1
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 1
- MEQLGHAMAUPOSJ-DCAQKATOSA-N Lys-Ser-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O MEQLGHAMAUPOSJ-DCAQKATOSA-N 0.000 description 1
- RPWTZTBIFGENIA-VOAKCMCISA-N Lys-Thr-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O RPWTZTBIFGENIA-VOAKCMCISA-N 0.000 description 1
- IHITVQKJXQQGLJ-LPEHRKFASA-N Met-Asn-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N IHITVQKJXQQGLJ-LPEHRKFASA-N 0.000 description 1
- OOSPRDCGTLQLBP-NHCYSSNCSA-N Met-Glu-Val Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OOSPRDCGTLQLBP-NHCYSSNCSA-N 0.000 description 1
- ZDJICAUBMUKVEJ-CIUDSAMLSA-N Met-Ser-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O ZDJICAUBMUKVEJ-CIUDSAMLSA-N 0.000 description 1
- RMLLCGYYVZKKRT-CIUDSAMLSA-N Met-Ser-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O RMLLCGYYVZKKRT-CIUDSAMLSA-N 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- MRNRMSDVVSKPGM-AVGNSLFASA-N Phe-Asn-Gln Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MRNRMSDVVSKPGM-AVGNSLFASA-N 0.000 description 1
- HBGFEEQFVBWYJQ-KBPBESRZSA-N Phe-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 HBGFEEQFVBWYJQ-KBPBESRZSA-N 0.000 description 1
- MJQFZGOIVBDIMZ-WHOFXGATSA-N Phe-Ile-Gly Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)O MJQFZGOIVBDIMZ-WHOFXGATSA-N 0.000 description 1
- OSBADCBXAMSPQD-YESZJQIVSA-N Phe-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N OSBADCBXAMSPQD-YESZJQIVSA-N 0.000 description 1
- XOHJOMKCRLHGCY-UNQGMJICSA-N Phe-Pro-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOHJOMKCRLHGCY-UNQGMJICSA-N 0.000 description 1
- IEIFEYBAYFSRBQ-IHRRRGAJSA-N Phe-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N IEIFEYBAYFSRBQ-IHRRRGAJSA-N 0.000 description 1
- GRIRJQGZZJVANI-CYDGBPFRSA-N Pro-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1 GRIRJQGZZJVANI-CYDGBPFRSA-N 0.000 description 1
- XROLYVMNVIKVEM-BQBZGAKWSA-N Pro-Asn-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O XROLYVMNVIKVEM-BQBZGAKWSA-N 0.000 description 1
- CJZTUKSFZUSNCC-FXQIFTODSA-N Pro-Asp-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1 CJZTUKSFZUSNCC-FXQIFTODSA-N 0.000 description 1
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 1
- SUENWIFTSTWUKD-AVGNSLFASA-N Pro-Leu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O SUENWIFTSTWUKD-AVGNSLFASA-N 0.000 description 1
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 description 1
- FZXSYIPVAFVYBH-KKUMJFAQSA-N Pro-Tyr-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O FZXSYIPVAFVYBH-KKUMJFAQSA-N 0.000 description 1
- 101710167959 Putative UTP-glucose-1-phosphate uridylyltransferase Proteins 0.000 description 1
- WXUBSIDKNMFAGS-IHRRRGAJSA-N Ser-Arg-Tyr Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@H](CO)N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WXUBSIDKNMFAGS-IHRRRGAJSA-N 0.000 description 1
- GWMXFEMMBHOKDX-AVGNSLFASA-N Ser-Gln-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 GWMXFEMMBHOKDX-AVGNSLFASA-N 0.000 description 1
- CJINPXGSKSZQNE-KBIXCLLPSA-N Ser-Ile-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O CJINPXGSKSZQNE-KBIXCLLPSA-N 0.000 description 1
- MOINZPRHJGTCHZ-MMWGEVLESA-N Ser-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N MOINZPRHJGTCHZ-MMWGEVLESA-N 0.000 description 1
- FUMGHWDRRFCKEP-CIUDSAMLSA-N Ser-Leu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O FUMGHWDRRFCKEP-CIUDSAMLSA-N 0.000 description 1
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 1
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 1
- WGDYNRCOQRERLZ-KKUMJFAQSA-N Ser-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)N WGDYNRCOQRERLZ-KKUMJFAQSA-N 0.000 description 1
- GDUZTEQRAOXYJS-SRVKXCTJSA-N Ser-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GDUZTEQRAOXYJS-SRVKXCTJSA-N 0.000 description 1
- ZKBKUWQVDWWSRI-BZSNNMDCSA-N Ser-Phe-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKBKUWQVDWWSRI-BZSNNMDCSA-N 0.000 description 1
- NVNPWELENFJOHH-CIUDSAMLSA-N Ser-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)N NVNPWELENFJOHH-CIUDSAMLSA-N 0.000 description 1
- ILZAUMFXKSIUEF-SRVKXCTJSA-N Ser-Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ILZAUMFXKSIUEF-SRVKXCTJSA-N 0.000 description 1
- UKKROEYWYIHWBD-ZKWXMUAHSA-N Ser-Val-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O UKKROEYWYIHWBD-ZKWXMUAHSA-N 0.000 description 1
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- XSLXHSYIVPGEER-KZVJFYERSA-N Thr-Ala-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XSLXHSYIVPGEER-KZVJFYERSA-N 0.000 description 1
- YBXMGKCLOPDEKA-NUMRIWBASA-N Thr-Asp-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O YBXMGKCLOPDEKA-NUMRIWBASA-N 0.000 description 1
- RCEHMXVEMNXRIW-IRIUXVKKSA-N Thr-Gln-Tyr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N)O RCEHMXVEMNXRIW-IRIUXVKKSA-N 0.000 description 1
- DXPURPNJDFCKKO-RHYQMDGZSA-N Thr-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DXPURPNJDFCKKO-RHYQMDGZSA-N 0.000 description 1
- XZUBGOYOGDRYFC-XGEHTFHBSA-N Thr-Ser-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(O)=O XZUBGOYOGDRYFC-XGEHTFHBSA-N 0.000 description 1
- NJGMALCNYAMYCB-JRQIVUDYSA-N Thr-Tyr-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O NJGMALCNYAMYCB-JRQIVUDYSA-N 0.000 description 1
- FYBFTPLPAXZBOY-KKHAAJSZSA-N Thr-Val-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O FYBFTPLPAXZBOY-KKHAAJSZSA-N 0.000 description 1
- CYDVHRFXDMDMGX-KKUMJFAQSA-N Tyr-Asn-His Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O CYDVHRFXDMDMGX-KKUMJFAQSA-N 0.000 description 1
- ZPFLBLFITJCBTP-QWRGUYRKSA-N Tyr-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O ZPFLBLFITJCBTP-QWRGUYRKSA-N 0.000 description 1
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- RUCNAYOMFXRIKJ-DCAQKATOSA-N Val-Ala-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN RUCNAYOMFXRIKJ-DCAQKATOSA-N 0.000 description 1
- QPZMOUMNTGTEFR-ZKWXMUAHSA-N Val-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N QPZMOUMNTGTEFR-ZKWXMUAHSA-N 0.000 description 1
- HURRXSNHCCSJHA-AUTRQRHGSA-N Val-Gln-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N HURRXSNHCCSJHA-AUTRQRHGSA-N 0.000 description 1
- VHRLUTIMTDOVCG-PEDHHIEDSA-N Val-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](C(C)C)N VHRLUTIMTDOVCG-PEDHHIEDSA-N 0.000 description 1
- FEXILLGKGGTLRI-NHCYSSNCSA-N Val-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N FEXILLGKGGTLRI-NHCYSSNCSA-N 0.000 description 1
- DIOSYUIWOQCXNR-ONGXEEELSA-N Val-Lys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O DIOSYUIWOQCXNR-ONGXEEELSA-N 0.000 description 1
- BGXVHVMJZCSOCA-AVGNSLFASA-N Val-Pro-Lys Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)N BGXVHVMJZCSOCA-AVGNSLFASA-N 0.000 description 1
- UGFMVXRXULGLNO-XPUUQOCRSA-N Val-Ser-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O UGFMVXRXULGLNO-XPUUQOCRSA-N 0.000 description 1
- AOILQMZPNLUXCM-AVGNSLFASA-N Val-Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN AOILQMZPNLUXCM-AVGNSLFASA-N 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010029539 arginyl-prolyl-proline Proteins 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000008809 cell oxidative stress Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 108010054813 diprotin B Proteins 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108010026364 glycyl-glycyl-leucine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 108010031424 isoleucyl-prolyl-proline Proteins 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 108010057952 lysyl-phenylalanyl-lysine Proteins 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108010056582 methionylglutamic acid Proteins 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 108010002837 tyrosyl-isoleucyl-phenylalanyl-valine Proteins 0.000 description 1
- 108010071635 tyrosyl-prolyl-arginine Proteins 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 229950010342 uridine triphosphate Drugs 0.000 description 1
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/91245—Nucleotidyltransferases (2.7.7)
- G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明提供一种用于诊断动脉粥样硬化的分子标志物UGP2及其应用,包括检测UGP2蛋白质的存在的试剂盒或诊断装置在制备用于诊断和/或预防和/或治疗动脉粥样硬化引起的疾病的药剂中的应用,所述试剂盒或诊断装置用于动脉粥样硬化引起的疾病的体外诊断和/或危险分层。本发明发现通过检测患者组织样品中的UGP2蛋白质浓度,可以预测动脉粥样硬化引起的疾病的发生,或对上述疾病进行诊断、危险分层等。
Description
技术领域
本发明涉及生物检测技术领域,特别是涉及一种用于诊断动脉粥样硬化的分子标志物UGP2及应用。
背景技术
心血管疾病是当前威胁全球人类健康的最重要的疾病之一,是发达国家的疾病和死亡的主要原因。根据世界心脏联盟的最新统计结果显示,每年全球死于心血管疾病的患者超过1700万人,已成为危害人类健康的全球第一杀手。中国的心血管疾病(CVD)现状同样令人堪忧。《中国心血管病报告2015》调查结果表明,2014年中国心血管病死亡率仍居疾病死亡构成的首位,高于肿瘤及其他疾病,CVD占居民疾病死亡构成在农村为44.60%,在城市为42.51%,每5例死亡者中就有2例死于CVD。中国心血管病危险因素流行趋势明显,心血管病的发病人数也在持续增加。
高脂血症与动脉粥样硬化(atherosclerosis,AS)、冠心病、脑卒中等心血管病关系密切已有共识,因此,寻找高血脂人群心血管疾病新型诊断标志物,对于早期干预、延缓疾病进展,减少死亡率与并发症发生率起着至关重要的作用。
目前本领域还没有一种成熟的心血管靶向治疗和检测方法,因此,急需研究开发新的特异性靶点和检测试剂盒,用于心血管疾病的预防和治疗。
发明内容
鉴于以上所述现有技术的缺点,本发明的目的在于提供一种用于诊断动脉粥样硬化的分子标志物UGP2及应用。
为实现上述目的及其他相关目的,本发明提供检测UGP2蛋白质的存在的试剂盒或诊断装置在制备用于诊断和/或预防和/或治疗动脉粥样硬化引起的疾病的药剂中的应用,所述试剂盒或诊断装置用于动脉粥样硬化引起的疾病的体外诊断和/或危险分层。
可选地,所述试剂盒用于检测体液样品中UGP2蛋白质的表达量。
可选地,所述试剂盒通过蛋白质印迹法、酶联免疫吸附测定、放射免疫分析、放射免疫扩散法、奥克特洛尼免疫扩散法、火箭免疫电泳、免疫组化染色、免疫沉淀分析法、补体结合分析法、流式细胞荧光分边技术和蛋白质芯片中的至少一种方法来检测UGP2蛋白质的表达量。
可选地,所述体液样品中UGP2蛋白质的表达量与动脉粥样硬化引起的疾病严重程度正相关。
可选地,所述体液样品选自血清。
可选地,所述药剂用于诊断或监测动脉粥样硬化引起的疾病的存在和/或过程和/或严重程度和/或预后。
本发明还提供UGP2(即尿苷二磷酸葡萄糖焦磷酸化酶2,UDP-glucosepyrophosphorylASe2)或其肽段作为生物标志物在制备或筛选动脉粥样硬化引起的疾病诊断试剂中的应用,所述诊断试剂用于动脉粥样硬化引起的疾病的体外诊断和/或危险分层。
可选地,所述动脉粥样硬化引起的疾病包括心血管疾病。
可选地,所述心血管疾病包括慢性心血管疾病。
可选地,所述慢性心血管疾病包括冠心病。
可选地,所述冠心病包括慢性冠心病、不稳定心绞痛、心肌梗死、稳定心绞痛。
可选地,动脉粥样硬化引起的疾病患者的UGP2蛋白质水平呈高表达。
本发明还提供用于表达UGP2蛋白质的DNA或其mRNA或保有其功能的同源物作为生物标志物在制备或筛选动脉粥样硬化引起的疾病的诊断试剂中的应用。
如上所述,本发明的用于诊断动脉粥样硬化的分子标志物UGP2及应用,具有以下有益效果:本发明发现通过检测患者组织样品中的UGP2蛋白质浓度,可以预测动脉粥样硬化引起的疾病的发生,或对上述疾病进行诊断、危险分层等。
附图说明
图1显示为本发明实施例1的基因芯片热图。
图2显示为本发明实施例1的浓度梯度Western Blot结果图。
图3显示为本发明实施例1的时间梯度Western Blot结果图。
具体实施方式
以下通过特定的具体实例说明本发明的实施方式,本领域技术人员可由本说明书所揭露的内容轻易地了解本发明的其他优点与功效。本发明还可以通过另外不同的具体实施方式加以实施或应用,本说明书中的各项细节也可以基于不同观点与应用,在没有背离本发明的精神下进行各种修饰或改变。
尿苷二磷酸葡萄糖焦磷酸化酶2(UDP-glucose pyrophosphorylASe 2,UGP2)基因定位于人类2号染色体的短臂上,全长49853bp,编码UDPG焦磷酸化酶,其氨基酸序列如序列1所示,其核苷酸序列(其mRNA对应的cDNA序列,不包含内含子和启动子序列)如序列2所示,NCBI上查询到的Gene ID如下:Gene ID:7360。在生理条件下,UDPG焦磷酸化酶可催化1-磷酸葡萄糖与尿苷三磷酸反应生成尿苷二磷酸葡萄糖(UDPG)及焦磷酸,UDPG可看作“活性葡萄糖”,在糖原合酶的作用下参与糖原的合成。由此可见,UGP2作为糖原合成起始途径的关键酶,通过催化葡萄糖转化生成UDPG并进一步生成糖原,在维持体内糖代谢平衡中发挥重要作用。研究表明,糖代谢紊乱与AS关系密切,高血糖可通过诱导血管内皮细胞和血管平滑肌细胞炎症反应,促进单核巨噬细胞向泡沫细胞转化和粥样斑块形成,因此,在临床表现为糖尿病患者出现AS的时间早、程度重和预后差。
在前期实验结果中,我们发现,与正常内膜组织相比,动脉斑块组织中UGP2表达明显上调。此外,在人脐静脉内皮细胞中,使用不同浓度、时间梯度Ox-LDL处理构建内皮细胞氧化应激受损模型,UGP2呈现递增的高表达量趋势。这些实验结果提示UGP2可能参与内皮细胞受损和AS进展。
目前本领域还没有一种成熟的针对UGP2的心血管靶向治疗和检测方法,因此,急需研究开发新的特异性靶点和检测试剂盒,用于心血管疾病的预防和治疗。
本发明涉及UGP2作为靶点用于预防和治疗心血管疾病,芯片结果分析显示UGP2在动脉粥样硬化病人动脉内膜组织和正常组织中差异表达明显,在内皮细胞氧化应激受损模型中,UGP2呈现明显的高表达量趋势。因此,UGP2可作为潜在的心血管疾病治疗靶点。
以下实施例中,图1涉及的实验方法参照文献:Xiao G,Martinez-Vaz B,Pan W,Khodursky AB.Operon information improves gene expression estimation for cDNAmicroarrays.BMC Genomics.2006;7:87.Published 2006Apr 21.doi:10.1186/1471-2164-7-87。
图2、图3涉及的实验方法参照文献:Gilda JE,Ghosh R,Cheah JX,West TM,Bodine SC,Gomes AV.Western Blotting Inaccuracies with Unverified Antibodies:Need for a Western Blotting Minimal Reporting Standard(WBMRS).PLoS One.2015;10(8):e0135392.Published 2015Aug 19.doi:10.1371/journal.pone.0135392。
实施例1
1、采用基因芯片分析AS病人动脉斑块组织和正常组织差异表达的mRNA水平,实验结果如图1所示,发现UGP2上调。
2、用0μg/ml、25μg/ml、50μg/ml、100μg/ml ox-LDL处理内皮细胞24h后经WesternBlot检测UGP2蛋白表达情况,实验结果如图2所示,我们从图中可以发现,UGP2蛋白水平随ox-LDL处理浓度增加,表达水平呈现递增的趋势,差异表达明显。
3、用100μg/ml ox-LDL处理内皮细胞0、6h、12h、24h后经Western Blot检测UGP2蛋白表达情况,实验结果如图3所示,我们从图中可以发现,UGP2蛋白水平随ox-LDL处理时间的增加,表达水平呈现递增的趋势,差异表达明显。
综上所述,本发明发现通过检测患者组织样品中的UGP2蛋白质浓度,可以预测动脉粥样硬化引起的疾病的发生,或对上述疾病进行诊断、危险分层等。
上述实施例仅例示性说明本发明的原理及其功效,而非用于限制本发明。任何熟悉此技术的人士皆可在不违背本发明的精神及范畴下,对上述实施例进行修饰或改变。因此,举凡所属技术领域中具有通常知识者在未脱离本发明所揭示的精神与技术思想下所完成的一切等效修饰或改变,仍应由本发明的权利要求所涵盖。
SEQUENCE LISTING
<110> 南方医科大学南方医院
<120> 用于诊断动脉粥样硬化的分子标志物UGP2及应用
<130> PCQNF192606
<160> 2
<170> PatentIn version 3.5
<210> 1
<211> 497
<212> PRT
<213> Artificial
<220>
<223> UGP2的氨基酸序列
<400> 1
Met Ser Gln Asp Gly Ala Ser Gln Phe Gln Glu Val Ile Arg Gln Glu
1 5 10 15
Leu Glu Leu Ser Val Lys Lys Glu Leu Glu Lys Ile Leu Thr Thr Ala
20 25 30
Ser Ser His Glu Phe Glu His Thr Lys Lys Asp Leu Asp Gly Phe Arg
35 40 45
Lys Leu Phe His Arg Phe Leu Gln Glu Lys Gly Pro Ser Val Asp Trp
50 55 60
Gly Lys Ile Gln Arg Pro Pro Glu Asp Ser Ile Gln Pro Tyr Glu Lys
65 70 75 80
Ile Lys Ala Arg Gly Leu Pro Asp Asn Ile Ser Ser Val Leu Asn Lys
85 90 95
Leu Val Val Val Lys Leu Asn Gly Gly Leu Gly Thr Ser Met Gly Cys
100 105 110
Lys Gly Pro Lys Ser Leu Ile Gly Val Arg Asn Glu Asn Thr Phe Leu
115 120 125
Asp Leu Thr Val Gln Gln Ile Glu His Leu Asn Lys Thr Tyr Asn Thr
130 135 140
Asp Val Pro Leu Val Leu Met Asn Ser Phe Asn Thr Asp Glu Asp Thr
145 150 155 160
Lys Lys Ile Leu Gln Lys Tyr Asn His Cys Arg Val Lys Ile Tyr Thr
165 170 175
Phe Asn Gln Ser Arg Tyr Pro Arg Ile Asn Lys Glu Ser Leu Leu Pro
180 185 190
Val Ala Lys Asp Val Ser Tyr Ser Gly Glu Asn Thr Glu Ala Trp Tyr
195 200 205
Pro Pro Gly His Gly Asp Ile Tyr Ala Ser Phe Tyr Asn Ser Gly Leu
210 215 220
Leu Asp Thr Phe Ile Gly Glu Gly Lys Glu Tyr Ile Phe Val Ser Asn
225 230 235 240
Ile Asp Asn Leu Gly Ala Thr Val Asp Leu Tyr Ile Leu Asn His Leu
245 250 255
Met Asn Pro Pro Asn Gly Lys Arg Cys Glu Phe Val Met Glu Val Thr
260 265 270
Asn Lys Thr Arg Ala Asp Val Lys Gly Gly Thr Leu Thr Gln Tyr Glu
275 280 285
Gly Lys Leu Arg Leu Val Glu Ile Ala Gln Val Pro Lys Ala His Val
290 295 300
Asp Glu Phe Lys Ser Val Ser Lys Phe Lys Ile Phe Asn Thr Asn Asn
305 310 315 320
Leu Trp Ile Ser Leu Ala Ala Val Lys Arg Leu Gln Glu Gln Asn Ala
325 330 335
Ile Asp Met Glu Ile Ile Val Asn Ala Lys Thr Leu Asp Gly Gly Leu
340 345 350
Asn Val Ile Gln Leu Glu Thr Ala Val Gly Ala Ala Ile Lys Ser Phe
355 360 365
Glu Asn Ser Leu Gly Ile Asn Val Pro Arg Ser Arg Phe Leu Pro Val
370 375 380
Lys Thr Thr Ser Asp Leu Leu Leu Val Met Ser Asn Leu Tyr Ser Leu
385 390 395 400
Asn Ala Gly Ser Leu Thr Met Ser Glu Lys Arg Glu Phe Pro Thr Val
405 410 415
Pro Leu Val Lys Leu Gly Ser Ser Phe Thr Lys Val Gln Asp Tyr Leu
420 425 430
Arg Arg Phe Glu Ser Ile Pro Asp Met Leu Glu Leu Asp His Leu Thr
435 440 445
Val Ser Gly Asp Val Thr Phe Gly Lys Asn Val Ser Leu Lys Gly Thr
450 455 460
Val Ile Ile Ile Ala Asn His Gly Asp Arg Ile Asp Ile Pro Pro Gly
465 470 475 480
Ala Val Leu Glu Asn Lys Ile Val Ser Gly Asn Leu Arg Ile Leu Asp
485 490 495
His
<210> 2
<211> 1494
<212> DNA
<213> Artificial
<220>
<223> UGP2的核苷酸序列
<400> 2
atgtctcaag atggtgcttc tcagttccaa gaagtcattc ggcaagagct agaattatct 60
gtgaagaagg aactagaaaa aatactcacc acagcatcat cacatgaatt tgagcacacc 120
aaaaaagacc tggatggatt tcggaagcta tttcatagat ttttgcaaga aaaggggcct 180
tctgtggatt ggggaaaaat ccagagaccc cctgaagatt cgattcaacc ctatgaaaag 240
ataaaggcca ggggcttgcc tgataatata tcttccgtgt tgaacaaact agtggtggtg 300
aaactcaatg gtggtttggg aaccagcatg ggctgcaaag gccctaaaag tctgattggt 360
gtgaggaatg agaatacctt tctggatctg actgttcagc aaattgaaca tttgaataaa 420
acctacaata cagatgttcc tcttgtttta atgaactctt ttaacacgga tgaagatacc 480
aaaaaaatac tacagaagta caatcattgt cgtgtgaaaa tctacacttt caatcaaagc 540
aggtacccga ggattaataa agaatcttta cttcctgtag caaaggacgt gtcttactca 600
ggggaaaata cagaagcttg gtaccctcca ggtcatggtg atatttacgc cagtttctac 660
aactctggat tgcttgatac ctttatagga gaaggcaaag agtatatttt tgtgtctaac 720
atagataatc tgggtgccac agtggatctg tatattctta atcatctaat gaacccaccc 780
aatggaaaac gctgtgaatt tgtcatggaa gtcacaaata aaacacgtgc agatgtaaag 840
ggcgggacac tcactcaata tgaaggcaaa ctgagactgg tggaaattgc tcaagtgcca 900
aaagcacatg tagacgagtt caagtctgta tcaaagttca aaatatttaa tacaaacaac 960
ctatggattt ctcttgcagc agttaaaaga ctgcaggagc aaaatgccat tgacatggaa 1020
atcattgtga atgcaaagac tttggatgga ggcctgaatg tcattcaatt agaaactgca 1080
gtaggggctg ccatcaaaag ttttgagaat tctctaggta ttaatgtgcc aaggagccgt 1140
tttctgcctg tcaaaaccac atcagatctc ttgctggtga tgtcaaacct ctatagtctt 1200
aatgcaggat ctctgacaat gagtgaaaag cgggaatttc ctacagtgcc cttggttaaa 1260
ttaggcagtt cttttacgaa ggttcaagat tatctaagaa gatttgaaag tataccagat 1320
atgcttgaat tggatcacct cacagtttca ggagatgtga catttggaaa aaatgtttca 1380
ttaaagggaa cggttatcat cattgcaaat catggtgaca gaattgatat cccacctgga 1440
gcagtattag agaacaagat tgtgtctgga aaccttcgca tcttggacca ctga 1494
Claims (10)
1.检测UGP2蛋白质的存在的试剂盒或诊断装置在制备用于诊断和/或预防和/或治疗动脉粥样硬化引起的疾病的药剂中的应用,所述试剂盒或诊断装置用于动脉粥样硬化引起的疾病的体外诊断和/或危险分层。
2.根据权利要求1所述的应用,其特征在于:所述试剂盒用于检测体液样品中UGP2蛋白质的表达量。
3.根据权利要求1所述的应用,其特征在于:所述试剂盒通过蛋白质印迹法、酶联免疫吸附测定、放射免疫分析、放射免疫扩散法、奥克特洛尼免疫扩散法、火箭免疫电泳、免疫组化染色、免疫沉淀分析法、补体结合分析法、流式细胞荧光分边技术和蛋白质芯片中的至少一种方法来检测UGP2蛋白质的表达量。
4.根据权利要求3所述的应用,其特征在于:所述体液样品中UGP2蛋白质的表达量与动脉粥样硬化引起的疾病严重程度正相关。
5.根据权利要求1所述的应用,其特征在于:所述药剂用于诊断或监测动脉粥样硬化引起的疾病的存在和/或过程和/或严重程度和/或预后。
6.根据权利要求2所述的应用,其特征在于:所述体液样品选自血清。
7.UGP2或其肽段作为生物标志物在制备或筛选动脉粥样硬化引起的疾病诊断试剂中的应用,所述诊断试剂用于动脉粥样硬化引起的疾病的体外诊断和/或危险分层。
8.根据权利要求7所述的应用,其特征在于:所述脉粥样硬化引起的疾病包括心血管疾病。
9.根据权利要求7所述的应用,其特征在于:动脉粥样硬化引起的疾病患者的UGP2蛋白质水平呈高表达。
10.用于表达UGP2蛋白质的DNA或其mRNA或保有其功能的同源物作为生物标志物在制备或筛选动脉粥样硬化引起的疾病的诊断试剂中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910250626.0A CN110093412A (zh) | 2019-03-29 | 2019-03-29 | 用于诊断动脉粥样硬化的分子标志物ugp2及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910250626.0A CN110093412A (zh) | 2019-03-29 | 2019-03-29 | 用于诊断动脉粥样硬化的分子标志物ugp2及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110093412A true CN110093412A (zh) | 2019-08-06 |
Family
ID=67444249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910250626.0A Pending CN110093412A (zh) | 2019-03-29 | 2019-03-29 | 用于诊断动脉粥样硬化的分子标志物ugp2及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110093412A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002079218A1 (en) * | 2001-03-30 | 2002-10-10 | Wyeth | Methods for diagnosing and treating multiple sclerosis and compositions thereof |
EP2458014A1 (en) * | 2010-09-07 | 2012-05-30 | Rijksuniversiteit Groningen | Prognostic markers for acute myeloid leukemia (AML) |
US20140100128A1 (en) * | 2012-09-12 | 2014-04-10 | Berg Llc | Use of markers in the identification of cardiotoxic agents and in the diagnosis and monitoring of cardiomyopathy and cardiovascular disease |
CN106461681A (zh) * | 2015-02-10 | 2017-02-22 | 梨花女子大学校产学协力团 | 用于诊断血管疾病的生物标志物及其用途 |
CN108210906A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 治疗冠状动脉粥样硬化及其并发症的药物及其用途 |
-
2019
- 2019-03-29 CN CN201910250626.0A patent/CN110093412A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002079218A1 (en) * | 2001-03-30 | 2002-10-10 | Wyeth | Methods for diagnosing and treating multiple sclerosis and compositions thereof |
EP2458014A1 (en) * | 2010-09-07 | 2012-05-30 | Rijksuniversiteit Groningen | Prognostic markers for acute myeloid leukemia (AML) |
US20140100128A1 (en) * | 2012-09-12 | 2014-04-10 | Berg Llc | Use of markers in the identification of cardiotoxic agents and in the diagnosis and monitoring of cardiomyopathy and cardiovascular disease |
CN106461681A (zh) * | 2015-02-10 | 2017-02-22 | 梨花女子大学校产学协力团 | 用于诊断血管疾病的生物标志物及其用途 |
CN108210906A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 治疗冠状动脉粥样硬化及其并发症的药物及其用途 |
Non-Patent Citations (3)
Title |
---|
H J M DE JONGE等: "Gene expression profiling in the leukemic stem cell-enriched CD34+ fraction identifies target genes that predict prognosis in normal karyotype AML", 《LEUKEMIA》 * |
SHENGLI LI等: "Transcriptome-Wide Analysis Reveals the Landscape of Aberrant Alternative Splicing Events in Liver Cancer", 《HEPATOLOGY》 * |
XIN HE等: "UGP2, a novel target gene of TP53, inhibits endothelial cells apoptosis and atherosclerosis", 《RESERCH SQUARE》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sawant et al. | Neutrophil to lymphocyte ratio predicts short-and long-term mortality following revascularization therapy for ST elevation myocardial infarction | |
Xing et al. | Clinical utility of biomarkers of endothelial activation in sepsis-a systematic review | |
Stanciu | Cytokines in heart failure | |
Yokokawa et al. | Significance of myocardial tenascin‐C expression in left ventricular remodelling and long‐term outcome in patients with dilated cardiomyopathy | |
CA2649562A1 (en) | Method and apparatus for diagnosing pre-eclampsia | |
Wang et al. | The haplotype of the growth-differentiation factor 15 gene is associated with left ventricular hypertrophy in human essential hypertension | |
KR102266302B1 (ko) | 심혈관 질환 또는 문제 위험 예측용 방법 및 키트 | |
JP2008515394A (ja) | 心臓の圧負荷関連遺伝子 | |
EP3140659A1 (en) | Methods for assessing differential risk for developing heart failure | |
Larsen et al. | The soluble receptor for advanced glycation end-products (sRAGE) has a dual phase-dependent association with residual cardiovascular risk after an acute coronary event | |
WO2010144553A2 (en) | Methods for diagnosing blood vessel reocclusion | |
CN106153945B (zh) | 一种检测缺血性脑卒中的生物标志物及其应用 | |
WO2007137405A1 (en) | Methods of diagnosing and treating rheumatoid arthritis and osteoarthritis | |
CN108913769A (zh) | 早期诊断心肌梗死的分子标志物 | |
WO2015157345A2 (en) | Bioenergetic profiling of circulating blood cells and systems, devices, and methods relating thereto | |
CN112180103A (zh) | 一种用于临床检测新冠肺炎患者血浆中活性尿激酶受体的试剂盒 | |
CN110093412A (zh) | 用于诊断动脉粥样硬化的分子标志物ugp2及应用 | |
KR20100059897A (ko) | 심혈관 및 혈전 위험도를 측정하기 위한 clec1b의 용도 | |
Ludka et al. | Comparison of NT-proBNP levels in hemodialysis versus peritoneal dialysis patients | |
CN111549114B (zh) | 心力衰竭的生物标志物及其应用 | |
Liu et al. | Correlation between virus persistent infection and cardic function in patients with dilated cardiomyopathy | |
CN114875130B (zh) | Lpin3蛋白或编码lpin3蛋白的基因在作为急性肾损伤的生物标志物中的应用 | |
EP2896964A1 (en) | MD-2 as biomarker in heart failure | |
CN112162097A (zh) | Gdf1作为评估pd-1单抗治疗效果的生物标志物 | |
CN110506125A (zh) | 用于预测骨髓应答和免疫应答的sh2b衔接蛋白3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190806 |